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Antibiotic consumption in pigs can be optimized by developing treatment guidelines, 
which encourage veterinarians to use effective drugs with low probability of develop-
ing resistance of importance for human health. In Denmark, treatment guidelines for 
use in swine production are currently under review at the Danish Veterinary and Food 
Administration. Use of pleuromutilins in swine has previously been associated with a 
very low risk for human health. However, recent international data and sporadic findings 
of novel resistance genes suggest a change of risk. Consequently, a reassessment 
was undertaken inspired by a risk assessment framework developed by the European 
Medicines Agency. Livestock-associated methicillin-resistant Staphylococcus aureus of 
clonal complex 398 (MRSA CC398) and enterococci were identified as relevant hazards. 
The release assessment showed that the probability of development of pleuromutilin 
resistance was high in MRSA CC398 (medium uncertainty) and low in enterococci (high 
uncertainty). A relatively small proportion of Danes has an occupational exposure to 
pigs, and foodborne transmission was only considered of relevance for enterococci, 
resulting in an altogether low exposure risk. The human consequences of infection with 
pleuromutilin-resistant MRSA CC398 or enterococci were assessed as low for the public 
in general but high for vulnerable groups such as hospitalized and immunocompromised 
persons. For MRSA CC398, the total risk was estimated as low (low uncertainty), among 
other due to the current guidelines on prevention of MRSA in place at Danish hospitals, 
which include screening of patients with daily contact to pigs on admittance. Moreover, 
MRSA CC398 has a medium human–human transmission potential. For enterococci, 
the total risk was estimated as low due to low prevalence of resistance, low probability 
of spread to humans, low virulence, but no screening of hospitalized patients, high ability 
of acquiring resistance genes, and a limited number of alternative antimicrobials (high 
uncertainty). This assessment reflects the current situation and should be repeated if 
pleuromutilin consumption increases substantially, resulting in increased prevalence 
of mobile, easily transmissible resistance mechanisms. Continuous monitoring of 
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pleuromutilin resistance in selected human pathogens should therefore be considered. 
This also includes monitoring of linezolid resistance, since resistance mechanisms for 
pleuromutilins and oxazolidones are often coupled.
Keywords: pleuromutilins, antimicrobial resistance, treatment guidelines, risk assessment, risk management, 
pigs, one health, human health
inTrODUcTiOn
In Denmark, all antimicrobials used for animals are prescribed 
by veterinary practitioners and sold through pharmacies or feed 
mills. Since year 2000, all antimicrobial prescription and sales 
records have been collated in a national database called VetStat. 
A prescription record includes information about type, concen-
tration and amount of the antimicrobial used, animals treated, 
indication, age group, herd identification, name of prescriber, and 
livestock producer (1).
Since 1995, antimicrobial consumption and antimicrobial 
resistance in bacteria from animals, food, and humans have been 
monitored routinely as part of a coordinated national program: 
Danish Integrated Antimicrobial Resistance Monitoring and 
Research program (DANMAP) (2). The monitoring of antimi-
crobial resistance covers three categories of bacteria: human and 
animal pathogens, zoonotic bacteria, and indicator bacteria. 
Each year, a DANMAP report summarizes the results of the 
monitoring program and related research, all available in: www.
danmap.org. The program is run by a One Health consortium of 
Statens Serum Institut, the National Veterinary Institute, and the 
National Food Institute.
The continuous surveillance has increased awareness of the 
relationship between antimicrobial consumption in animals and 
development of resistance. Several initiatives exist to control 
and reduce the consumption in pigs. These include the Specific 
Pathogen Free (SPF) health scheme, banning of growth promot-
ers, prohibition of prophylactic usage, and a control program 
called the “Yellow Card scheme,” introduced in 2010. This admin-
istrative system defines limits to antimicrobial consumption per 
age group within a swine herd per time period (3). These limits 
have further been reduced and enforced as the national average 
of consumption decreased (4). Recently, a weighting of different 
antimicrobial classes according to their potential for generating 
antimicrobial resistance was introduced in the scheme to steer 
prescribers toward certain antimicrobial choices (5).
In addition, a working group consisting of stakeholder 
representatives and headed by the Danish Veterinary and Food 
Administration developed the first generation of antimicrobial 
treatment guidelines for pigs in 2006. The guidelines help the 
veterinarian in choosing the most appropriate drug for the 
respective infectious disease encountered. In the most recent ver-
sion from 2010, the guidelines contain specific recommendations 
on the choice of drug as well as background information on the 
known percentage of resistance in the suspected causal pathogen, 
pharmacodynamics of the drug, and the probability of develop-
ment of antimicrobial resistance transmissible to humans.
The first Danish guidelines were developed without formal 
risk assessments, and this led to some controversy regarding 
the assessment of macrolides, resulting in a more thorough 
estimation of this risk (6). In the newest version, a simplified 
risk assessment approach developed by the US authorities (7) 
was used, resulting in a broader acceptance of the guidelines 
by the stakeholders. The possible impact on human health 
regarding each antimicrobial class was assessed using a scale 
with four levels: very high, high, medium, and low. Third and 
fourth generations’ cephalosporins and fluoroquinolones were 
considered to be of very high risk for the development of ESBL-
producing or fluoroquinolone-resistant bacteria and for trans-
mission to humans of these, therefore, these antimicrobial classes 
were recommended not to be used. Ampicillin/amoxicillin, 
gentamycin/apramycin, tylosin/lincomycin, and tetracyclines 
were assessed to have a high risk, and their use should therefore 
be limited. Florfenicol, penicillin, tulathromycin/tilmicosin, 
and sulfonamide/trimethroprim were assessed as medium risk, 
and neomycin, colistin, and pleuromutilins as low or very low 
risk (7).
Currently, the guidelines are being revised. The part of 
the guidelines that cover the assessment on the risk to human 
health is built on a risk assessment framework inspired by a set 
of guidelines issued by the European Medicines Agency (EMA) 
in February 2015 (8). Currently, these guidelines exist only in a 
drafted version.
In this article, the risk assessment for pleuromutilins will be 
presented. Pleuromutilins consist of a class of antimicrobials, of 
which tiamulin and valnemulin are of veterinary use exclusively 
and primarily used to treat diseases in swine. Pleuromutilins have 
so far been associated with a low probability of development of 
antimicrobial resistance of importance for human health, since 
no equivalent drug exists for human treatment and no impor-
tant cross-resistances to other human antimicrobials have been 
described. In the 2010 version of the Danish treatment guidelines, 
tiamulin and valnemulin were therefore recommended for treat-
ment of relevant infections in swine (see Hazard identification 
section for a specification).
However, it was decided to reassess the risk related to the use 
of pleuromutilins in Danish swine due to:
 1. New knowledge on resistance to pleuromutilins emerg-
ing on mobile elements in staphylococci and enterococci 
among other, making horizontal transmission and coselec-
tion of other critical resistances such as linezolid resistance 
possible.
 2. The potential selection of pleuromutilin-resistant staphylo-
cocci [including livestock-associated methicillin-resistant 
Staphylococcus aureus (MRSA) of clonal complex 398, MRSA 
CC398] in swine treated with pleuromutilins indicated by 
international literature (9).
FigUre 1 | a schematic framework illustrating the risk pathway from consumption of pleuromutilin in pigs to the risk to public health.
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 3. Possible increased importance of pleuromutilins for the 
treatment of humans due to new product developments (9).
 4.  Expectations on an increase in the use of pleuromutilins in the 
Danish swine production due to changes in the Danish Yellow 
Card scheme using weighting of the different antimicrobial 
classes.
The objective of this article is to assess the risk for human 
health associated with the use of pleuromutilins in the Danish 
swine production.
MaTerials anD MeThODs
Materials
The risk assessment used several sources of information, the 
primary source being Danish data obtained through Danish 
surveillance programs and research. For each aspect, the newest 
data available were obtained. Data describing the consumption of 
pleuromutilins in Danish livestock in 2015 were obtained from 
VetStat. The Danish pleuromutilin consumption was compared 
with that of other European countries using data from ESVAC 2010 
reported by EMA (9). Data from DANMAP 2015 were obtained 
to describe the prevalence of resistance observed in Denmark (2). 
The Danish-resistance data were compared to EU data from 2013 
(10). A central source was the EMA’s reflection paper from 2013, 
regarding the use of pleuromutilins in food-producing animals 
in the European Union (9). Finally, various scientific publications 
were used for scientific information required to assess the risk 
for humans related to the use of pleuromutilins in Danish swine.
Methods
We applied an adapted version of EMA’s framework on assess-
ment of risk to public health from antimicrobial resistance due to 
the use of an antimicrobial veterinary product in food-producing 
animals (8). In essence, it follows the International Organization 
for Animal Health’s (OIE) approach to risk assessment and con-
sists of four steps describing the risk pathway combined into a 
risk estimate (Figure 1).
The first step was the hazard identification. This step identified 
antimicrobial-resistant bacteria or resistance determinants that 
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could result in human illness and, hence, may be selected due to 
the use of pleuromutilins in Danish swine. Hazards for further 
analysis were identified by literature and expert opinion, and a 
preliminary assessment through the four steps of the risk pathway 
was carried out (Figure 1). If the hazard had potential to fulfill 
all steps in the risk pathway, it was included in the subsequent 
risk assessment. Lack of information in any important step also 
excluded potential hazard from further analysis.
The second step was the release assessment. In this step, the 
presence and multitude of the identified hazards in the swine 
reservoir as a result of the use of pleuromutilins in Danish swine 
were described and assessed.
The third step was the exposure assessment, which addressed 
the biological pathways necessary for exposure of humans to the 
identified hazards, which are the selected resistances from the 
release from swine. The exposure assessment addressed the two 
main pathways from pigs to humans: meat and direct contact. 
An exposure was defined as a contact that resulted in the person 
becoming either carrier or infected by the hazard. Each route was 
considered separately and combined into one exposure assess-
ment score per hazard for the Danish situation.
A scale was used to describe the probability of release and 
exposure: very low (<2%), low (2–10%), medium (11–30%), and 
high (>30%).
The fourth step was the consequence assessment. The conse-
quences of infection by resistant hazards caused by pleuromutilin 
consumption in pigs were assessed by two effects: (1) an increase 
in public health burden or (2) prolonged human illness and/or 
death. The public health burden was defined as a marked increase 
in the total number of carriers or infected people. This could pose 
a risk to society due to increased expenses related to the control 
of spread (screening and isolation procedures of patients), loss 
of work days, and an overall higher risk of severe illness due to 
increased exposure. Prolonged illness and/or death were meas-
ures for the severity of treatment failure in the individual patient 
due to resistance caused by pleuromutilin usage in pigs. Each 
consequence was assessed on a scale of very low, low, medium, 
or high based on the increase in cases caused by the resistance 
and the importance of the pleuromutilin and related antibiotics 
in treatment in Denmark.
The risk estimate was a summary of the steps above, and it 
was based on a combination of the probability of the unwanted 
event and the associated consequences. If any of the probabilities 
related to release, exposure, or consequences were zero, there 
would be no risk.
The level of uncertainty was described as high, medium, or low. 
Low uncertainty was used, where abundant data pointing in one 
direction were available, medium where only a limited amount of 
data were available, and high where no data were available, and 
expert opinion had to be used instead.
A detailed description of what is included in the different 
elements is described by EMA (8), and a qualitative assessment 
is recommended in the presence of substantial data gaps. Any 
deviation due to lack of data has been indicated.
The EMA framework is very detailed and thereby contains 
many elements, reflecting its purpose as a tool of risk assess-
ment in regard to application for marketing authorizations for 
new antimicrobial classes (8). Pleuromutilins have been used for 
veterinary purposes for decades, and therefore, direct data are 
available describing consumption, resistance, transmission, and 
consequences. Some of the listed elements were therefore found 
to be of no relevance for the present exercise and were therefore 
excluded from this article.
resUlTs
hazard identification
Pleuromutilin Consumption in Denmark
Pleuromutilins for treatment of swine entered the Danish market 
in the early 1980s. The antimicrobial class pleuromutilins includes 
tiamulin and valnemulin, which are semisynthetic derivatives 
(11, 12). In Denmark, they are registered for indications including 
porcine proliferative enteropathy (due to Lawsonia intracellularis), 
swine dysentery (due to Brachyspira hyodysenteriae), porcine 
colonic spirochetosis (due to Brachyspira pilosicoli), enzootic 
pneumonia (due to Mycoplasma hyopneumoniae), infections 
caused by Mycoplasma hyorhinis and M. hyosynoviae, and respira-
tory diseases caused by tiamulin-sensitive microorganisms (13). 
They can be administered either by injection or added to feed or 
water, allowing both individual and group treatment (14).
Almost all pleuromutilins (99.9%) prescribed for Danish 
livestock are used in swine production, and the main area of use 
is group treatments, which is usually short term. In 2015, the 
annual consumption measured in active kilogram compound was 
7,878 kg (2). This is close to the lowest consumption measured in 
2011 and 2012, following the implementations of the yellow card 
scheme and the new revised version of the treatment guidelines 
(15). In 2015, the consumption corresponded to 10% of the total 
use of antimicrobials in swine in Denmark (2). Based on the 
consumption in kilogram, half of the amount (51%) was used in 
finishing pigs, 39% in weaner pigs, and 10% in sows and piglets. 
When measured in the daily dose per 1,000 animals (DAPD), 
the consumption has varied from 3 to 6 DAPD during the past 
decade, also here the fluctuations observed mirror the mentioned 
effect of the initiatives on prudent use and reduction (2). In 2015, 
the consumption was 4.4 DAPD.
Between the European countries, a large variation in consump-
tion of pleuromutilins is observed. In 2010, the top five countries 
were Portugal, Hungary, Spain, Czech Republic, and the United 
Kingdom, whereas Denmark figured toward the lower end (9).
For the treatment of humans, only one pleuromutilin-containing 
product, called Retapamulin, was previously registered on the 
Danish market but was withdrawn in 2014, probably due to low 
sales. Retapamulin was licensed for topical use for the treatment 
of impetigo and infected small lacerations, abrasions, or sutured 
wounds.
A new pleuromutilin, called Lefamulin, is currently under 
development and entered its second phase III clinical trial in April 
2016 (16). Lefamulin is developed to be the first pleuromutilin for 
systemic use in humans. In microbiological studies, Lefamulin 
showed potent in vitro activity against S. pneumoniae, H. influenzae, 
M. pneumoniae, L. pneumophila, and C. pneumoniae, as well as 
S. aureus, including multidrug resistant strains of S. pneumonia 
and MRSA. In Denmark, only the latter seems relevant for future 
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treatment with Lefamulin, since the occurrence of drug resistance 
in the other target bacteria is very low and hardly any multi drug 
resistance is found in these (2). This drug is expected to be regis-
tered for the treatment of serious pneumonia and may also find 
its use in the treatment of rare cases of genital tract infections 
with multidrug-resistant Ureaplasma. The US authorities FDA 
have granted fast track designation to the oral formulation of 
Lefamulin to facilitate the development of a drug that is able to 
treat serious conditions and fill an unmet medical need (16). 
This increases the need to focus on how to limit the probability 
of developing pleuromutilin resistance and to monitor resistance 
development.
Pleuromutilins are closely related to oxazolidones due to very 
similar chemical structures and coresistance might thus occur. In 
Denmark, two oxazolidones are registered for human treatment: 
Tedizolidphosphat and linezolid. Tedizolidphosphat is only reg-
istered for specific and complicated skin structure infections, and 
the consumption is negligible. Linezolid is registered for the treat-
ment of severe infections with gram-positives. It is recommended 
for complicated infections only and where other antimicrobials 
cannot be used, either due to allergies or due to development of 
resistance. The consumption of linezolid is only minor compared 
to other antimicrobial classes and currently accounts for less than 
0.5% of the total consumption at hospitals and close to 0% in pri-
mary health care in Denmark (2). Treatment periods of more than 
28 days are not recommended due to the risk of adverse effects. 
To date, linezolid is primarily used in hospitals for complicated 
staphylococcal bone infections, for the treatment of complicated 
infections with MRSA, and for the treatment of severe infections 
with penicillin-resistant pneumococci in Denmark. It is also 
registered for the treatment of infectious endocarditis caused by 
vancomycin-resistant enterococci (VRE), but very rarely used, 
since this is an extremely rarely occurring condition. It is, thus, 
considered a last line drug.
Known Resistance Determinants
Usage of pleuromutilins in pigs may influence public health in the 
following ways (Figure 1):
 1. Induce and select chromosomal resistance by point mutations 
in the 23S rRNA and rplC genes and thereby
 i. exhibit cross-resistance to linezolid.
 2. Induce and select plasmid-borne resistance via transferable 
resistance genes cfr and vga and thereby
 i. exhibit cross- and coselection of resistance to or from other 
antibiotic groups.
 3. Select for already pleuromutilin-resistant bacteria.
Emergence of resistance due to chromosomal point mutations 
is usually not considered critical due to a limited capacity to spread, 
unless the resistant clone has a high pathogenicity or its ability to 
spread between humans for some reason is high. However, some 
of the pleuromutilin point mutations in Staphylococcus spp. have 
been found to lead to cross-resistance with linezolid (17, 18). 
Point mutation-driven resistance to pleuromutilin has also been 
reported to gradually reduce susceptibility in Brachyspirae in pigs, 
making continued use in swine herds of some concern due to the 
risk of treatment failure in these (19–21). This has no direct effect 
on human health since Brachyspirae only very rarely cause human 
disease, but similar mechanisms in human bacteria may be of 
concern for human treatment if the drug is to be used extensively 
in humans in the future.
Pleuromutilin resistance may also develop as or be acquired by 
horizontal transfer of mobile genetic elements such as plasmids 
or transposons containing resistance genes and might spread not 
only within but also between bacterial species. Such elements are 
more likely to spread at a high speed among bacterial popula-
tions than resistance driven by point mutations and may affect 
the susceptibility of important human pathogens rapidly. Among 
these there are several gene families of relevance to pleuromutilin 
usage: the methyltransferase genes cfr and the vga ABC trans-
porter genes (22–25).
cfr genes can confer multidrug resistance and have great 
potential to spread. They have been found in staphylococci 
of pig origin including MRSA CC398 (26, 27). cfr genes can 
confer cross-resistance between pleuromutilins, lincosamides, 
streptogramin A, phenicols, and oxazolidinones (=linezolid) 
(9, 25). However, a national prevalence survey of MRSA CC398 
in pigs in Denmark in 2014 did not reveal any cfr genes in the 
275 MRSA CC398 isolates (Personal communication, J. Larsen, 
Statens Serum Institut, 2017). A cfr-like gene conferring pheno-
typic resistance with high MIC for especially clindamycin and 
linezolid was reported in different Bacillales and in a Danish 
strain of Clostridium difficile. It is yet to be established whether 
this has any clinical importance in humans in Denmark (28). 
cfr genes have also been reported in enterococci from animal 
origin in China (29). No further reports on a significant spread 
of cfr genes in enterococci were found from other countries, 
but the occurrence of cfr genes in enterococci is worrying since 
enterococci have high ability to share plasmids.
The ABC transporters induce cross-resistance between 
pleuromutilins, lincosamides, and streptogramin A and have the 
potential to cross-select for further antimicrobial classes (30, 31). 
The possibility for coresistance to other antimicrobial classes will 
depend on the mobile genetic elements circulating in the bacte-
rial population. Plasmids carrying vga(C) genes have been found 
to contain the tetracycline-resistance gene tet(L), the kanamycin/
neomycin-resistance gene aadD, and the trimethoprim-resist-
ance gene dfrK (32). Staphylococci carrying vga(E) genes were 
also found resistant to beta-lactams, tetracyclines, trimethoprim, 
macrolides, lincosamides, and spectinomycin and resistant to 
or with reduced susceptibility to quinupristin/dalfopristin (33). 
The 275 MRSA CC398 from the pig survey in Denmark in 2014 
revealed only one isolate carrying a vga gene (Personal commu-
nication, J. Larsen, Statens Serum Institut, 2017).
Other mobile-resistance elements such as optrA genes have 
been reported in pork in other countries, but in Denmark, the 
optrA gene has to date only been reported in three enterococcal 
isolates from imported turkey, one isolate from Danish calf, and 
one human clinical Enterococcus faecalis isolate (34). They confer 
resistance to phenicols and the newest generation of oxazoli-
dinones including linezolid (35–38). optrA genes do not confer 
resistance to pleuromutilines but might be carried together with 
cfr genes on the same plasmid (37). Thus, the coselection with 
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pleuromutilins resistance may result in wider spread, if the con-
sumption of pleuromutilins increases.
The use of pleuromutilins may thus excerpt a selective pressure 
for multidrug resistant staphylococci, enterococci, and other 
gram-positives, if the level of pleuromutilin resistance increases.
Hence, the main risk of pleuromutilin usage in pigs is mul-
tiresistance transfer and development of coresistance to linezolid, 
which is a last line antibiotic in humans.
Potential Bacterial Species of Importance for  
Human Health
Pleuromutilin resistance is not routinely monitored in Denmark 
(2). Theoretically, resistance may develop in all treatment targeted 
pathogens: Brachyspirae, Mycoplasma spp., and Lawsonia and 
other pig pathogens such as Actinobacillus, Erysipelothrix, and 
Pasteurella. Data from the Danish swine industry’s laboratory in 
Kjellerup show that all 210 tested A. pleuropneumoniae isolates 
from diseased pigs were sensitive to pleuromutilins. No informa-
tion regarding B. hyodysenteria was available at the laboratory due 
to dysentery being very uncommon in Danish pig production 
(Personal comment, B. Svensmark, SEGES, 2017). A Swedish 
study testing clinical isolates of Brachyspira hyodysenteriae and 
B. pilosicoli showed slowly increasing resistances over a 20-year 
period (from 1990 till 2010) and declining resistances for the last 
2–3 years of the study (19). Recent Swedish surveillance data have 
revealed that 94% of 69 Swedish B. hyodysenteria isolates were 
sensitive to tiamulin (39). Hence, the level of resistance in these 
microorganisms is considered to be low. Moreover, these organ-
isms very rarely cause disease in humans. They were therefore not 
considered relevant for this risk assessment.
Anaerobe species such as Clostridium spp. and specifically 
Clostridium difficile were considered to be of potential relevance, 
as they can spread from pigs to humans. As mentioned previously, 
observation of cfr genes and pleuromutilin resistance in a strain 
of C. difficile has been reported (28), but the involved isolate was 
not associated with resistance to metronidazole, vancomycin, 
or fidaxomicine, which are used to treat human clostridial gas-
trointestinal infections in Denmark. Furthermore, linezolid is 
not used for treatment of cases with other anaerobic bacteria in 
Denmark. No standard testing methods or EUCAST breakpoints 
for pleuromutilins or linezolid have been defined for anaerobic 
bacteria, and occurrence of resistance in these pathogens has 
yet to be explored. Due to the lack of resistance data, anaerobe 
bacteria such as Clostridia and C. difficile were not included as 
hazards in this risk assessment.
In enterobacteriaceae, no resistance mechanisms related to 
pleuromutilin have been reported, despite experimental studies 
suggesting a hypothetical possibility (40). Enterobacteriaceae 
were therefore excluded from this analysis.
Enterococci have been proven to be transmitted from either 
live animals or meat to man and do easily exchange resistance 
genes within the genera (41–43). Enterococci frequently cause 
urinary tract infections in humans. Enterococcus faecalis is also 
associated with serious infections such as bacteremia, surgical 
infections, and infectious endocarditis. Enterococcus faecium is 
usually considered a commensal with very low pathogenicity, but 
catheter-related infections and infectious endocarditis have been 
described. Serious infections with enterococci occur primarily 
in immunocompromised patients, and in these patients the 
mortality is high. Since 2013, one outbreak due to a clonal spread 
of a VRE E. faecium has been observed in hospitals in the capital 
region of Denmark and in the region of Zealand. The incidence 
of this VRE clone has been steeply increasing, which suggests 
that importance of linezolid in treatment will also increase in the 
future.
Enterococcus spp. were thus defined as a relevant hazard in our 
analysis, despite high uncertainty due to lack of surveillance data. 
It was included, because both resistant strains and their relevant 
resistance genes may spread from pigs to humans, and the con-
sequences of development of linezolid resistance in Enterococcus 
spp. could be highly severe (30, 36). Staphylococci are known 
to spread from pigs to humans in persons frequently handling 
these animals, and extensive research has been carried out on the 
transmission of S. aureus (44–46). S. aureus is one of the major 
bacterial pathogens causing infections in humans in Denmark. 
The infections range from skin and soft tissue to joint and bone 
infections—and in more severe cases infection leads to bacteremia 
and infectious endocarditis. S. aureus accounts for 10–15% of all 
bacteremia in Denmark (47). In recent years, the total number of 
bacteremias has been slightly decreasing while bacteremias caused 
by staphylococci have been increasing (48, 49).
The livestock-associated MRSA CC398 is widespread in 
Danish swine herds and frequent transfer to humans is well 
documented (44–46). MRSA CC398 behaves like other S. aureus 
and was defined as a relevant hazard in the analysis, because 
pleuromutilin resistance has been found both on chromosomes 
and on plasmids. Coagulase-negative staphylococci may also be 
transmitted to humans but are considered a human commensal 
and not a significant pathogen. Resistance mechanisms may be 
transmitted from these to other human gram-positive bacteria. 
It was assumed that this mechanism is the same as for S. aureus. 
Thus, MRSA CC398 was considered a relevant hazard for the 
analysis, but non-MRSA staphylococci were not.
Conclusion for the Hazard Identification
Two pathogens were identified as relevant hazards for transfer-
ring resistance to humans due to the current and future use of 
pleuromutilins in Danish pigs: enterococci and MRSA CC398. 
Resistance may be chromosomal (staphylococci) or mobile—
either carried by transposons or plasmids (staphylococci and 
enterococci). Anaerobe bacteria such as Clostridium were also 
described to carry resistance genes of relevance, but to date 
neither pleuromutilins nor linezolid are used for the treatment of 
infections with these bacteria. In addition, there is no surveillance 
of these resistance mechanisms in human anaerobe bacteria. 
Therefore, these hazards were not included in the risk assessment.
release assessment
Prevalence of MRSA CC398 and Enterococci  
in the Danish Swine Population and Current  
Levels of Resistance to Pleuromutilins
In 2014, a survey was undertaken in Danish swine herds to assess 
the between-herd prevalence of MRSA CC398. A total of 63% of 
Table 1 | Prevalence of resistance (%)a among Enterococcus faecalis 
(DanMaP 2015) and MRSA CC398 from humans as well as swine and 
pork, 2014.
antimicrobial 
agent
Prevalence (%) of resistance in
E. faecalis Mrsa cc398d
Pigsb Danish 
pork
imported 
pork
humanc Danish 
pork
Tetracycline 72 14 44 100 9
Chloramphenicol 15 4 0 n.a. 0
Ampicillin 0 0 0 n.a. 4
Erythromycin 35 6 11 43 0
Linezolid 0 0 0 0 0
TMP n.a. n.a. n.a. 1 n.a.
Sulfonamide n.a. n.a. n.a. 1 n.a.
Clindamycin n.a. n.a. n.a. 87 n.a.
Kanamycin n.a. n.a. n.a. 7 n.a.
No. of samples 40 120 27 68 23
Source: Ref. (2).
aSelected for antibiotic classes, which have shown to have co- and cross-resistance to 
pleuromutilins.
bIsolates derive from samples taken from healthy pigs at slaughter (2).
cIsolates derived from human MRSA CC398 cases.
dData from a point prevalence study in 2014, DANMAP 2014.
DANMAP, Danish Integrated Antimicrobial Resistance Monitoring and Research 
Program; MRSA, methicillin-resistant S. aureus; n.a., not applicable/not examined.
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the participating breeding herds (N = 70) and 68% of the finishing 
pig herds (N = 205) were found to be carriers (50). No phenotypic 
resistance testing of the 275 MRSA CC398 isolates was undertaken.
Two Danish studies published in 2012 assessed the prevalence 
of MRSA CC398 in different age groups of pigs longitudinally 
(51, 52). The first study compared the distribution of MRSA 
CC398 in two herds. In one herd, MRSA CC398 was present in 
all sampled animals and in all age groups (sows, piglets, weaners, 
and finishers). In the other herd, sampled weaners and finish-
ers were MRSA CC398 positive at all sampling occasions, while 
the temporal prevalence in piglets and sows was slightly lower 
(68–92%) (51). In the other study undertaken in six Danish swine 
herds, the average prevalence was higher (99%) among weaners 
than observed in pregnant sows (34%), piglets (77%), and finish-
ing pigs (67%) (52).
A study conducted at the Danish National Food Institute 
on MRSA and methicillin-sensitive S. aureus (MSSA) of swine 
origin showed that all of MRSA CC30 strains tested and 30% 
of the MRSA CC398 tested were resistant to tiamulin, while the 
MSSA strains of CC30 and CC398 showed 46 and 38% resistance, 
respectively. This indicates a high prevalence of phenotypic resist-
ance, however, the resistance mechanisms were not identified 
(53). In the survey performed through the Danish Veterinary and 
Food Adminnistration in 2014, 63% of the examined 70 breeding 
herds were found positive for MRSA CC398 and 68% of the 205 
examined herds with finisher pigs (50). Data from the Danish 
swine industry’s laboratory in Kjellerup show that 61% of 36 S. 
aureus isolates from submission of diseased pigs were sensitive to 
pleuromutilin (Personal communication B. Svensmark, 2017). A 
small study on Danish mink farms showed resistance to tiamulin 
in 79.5% of the 39 MRSA CC398 isolates found. In Denmark, mink 
are fed with animal byproducts primarily consisting of slaughter-
house offal from pigs and poultry. The findings of MRSA CC398 
in mink point toward transmission from pigs to mink through 
the feed (Personal communication K. Pedersen, DTU VET, 2017).
Resistance to pleuromutilins or linezolid is not investigated 
as part of DANMAP (2). According to DANMAP 2015, MRSA 
CC398 isolates are typically resistant to tetracycline (100%) and 
clindamycin (87%) with high levels of resistance to erythromycin 
(43%) (Table 1).
Enterococci are part of the normal intestinal microbiota of 
pigs and exist in abundance, thus it is expected that enterococci 
are also found on the living pig and are ubiquitous in the stable 
and surroundings. The prevalence of E. faecalis in pig cecal con-
tent at slaughter in 2015 was 24.7% (personal communication J. 
Ellis-Iversen, DTU-Food, 2017).
Resistance to pleuromutilin in enterococci has not been 
monitored in Denmark, and no international literature on the 
subject was found, so the release assessment is associated with 
large uncertainty.
Resistance to linezolid has been monitored in Enterococcus spp. 
in Denmark since 2002, involving annual susceptibility testing of 
isolates from Danish pigs at slaughter and Danish and imported 
pork. To date, no isolates have exhibited phenotypical resistance 
to linezolid. In 2015, 40 isolates of E. faecalis from pigs were 
tested, and all found sensitive to linezolid (Table 2). In Table 1, 
resistance surveillance data in gram-positive bacteria is shown 
for comparison. It is noted that resistance against tetracycline 
(72%) and erythromycin (35%) is very common in pig isolates of 
E. faecalis (Table 1).
Conclusion for the Release Assessment
The overall probability of release of pleuromutilin-resistant MRSA 
CC398 and enterococci from pigs as a result of the use of pleuro-
mutilins in Danish pigs was considered high for MRSA CC398 
(medium uncertainty) and low for enterococci (high uncertainty).
A limited amount of data was available as pleuromutilin 
resistance is not systematically monitored in Denmark. The 
screening of a national representative pool of MRSA CC398 for 
mobile-resistance genes reduces the uncertainty score around the 
MRSA CC398 estimate to medium, but the uncertainty around 
the enterococci remained high due to lack of data.
The probability for cross-resistance to linezolid was considered 
to be medium for MRSA CC398 due to possible chromosomal 
point mutations (high uncertainty) and very low for enterococci 
(low uncertainty).
exposure assessment
Exposure to MRSA CC398 and Enterococci via Meat
In Denmark, pork is the most commonly consumed type of meat. 
The consumption of pork per capita is 56 kg per year, followed by 
beef (27 kg) and poultry (26 kg). In comparison, the average con-
sumption of pork in EU-27 is 40 kg, followed by poultry (24 kg) 
and beef (15 kg) (54). Most pork is eaten cooked and a minority 
as ready-to-eat cured products, which is expected to reduce the 
presence of all bacterial pathogens.
Between 2009 and 2011, Danish Veterinary and Food 
Administration undertook a survey for presence of MRSA 
CC398 in fresh meat. The average prevalence was 4% in Danish 
Table 2 | results from Danish surveys of linezolid resistance in Enterococcus faecalis and Enterococcus faecium in pigs and pork, respectively.
Year E. faecalis in pigs E. faecalis in pork E. faecium in pigs E. faecium in pork
examined (no.) resistance (%) examined (no.) resistance (%) examined (no.) resistance (%) examined (no.) resistance (%)
2002 238 0 42 0 194 0 28 0
2003 207 0 78 0 175 0 45 0
2004 153 0 172 (12 imported) 0 148 0 52 0
2005 119 0 n.a. n.a. 105 0 n.a. n.a.
2006 154 0 n.a. n.a. 145 0 n.a. n.a.
2007 148 0 n.a. n.a. 151 0 n.a. n.a.
2008 149 0 197 (125 imported) 0 145 0 31 (16 imported) 0
2009 133 0 215 (109 imported) 0 151 0 39 (22 imported) 0
2010 157 0 175 (91 imported) 0 133 0 29 0
2011 117 0 178 (45 imported) 0 116 0 27 0
2012 119 0 212 (108 imported) 0 112 0 54 (22 imported) 0
2013 109 0 190 (140 imported) 0 n.a. n.a. 53 (31 imported) 0
2014 142 0 214 (105 imported) 0 n.a. n.a. 23 0
2015 40 0 120 (27 imported) 0 n.a. n.a. n.a. n.a.
Source: Ref. (2).
n.a., not applicable/not examined.
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and imported pork, 1–2% in Danish and imported beef, and 15% 
in the imported poultry meat. The samples were analyzed quali-
tatively (presence/nonpresence) (55). These figures are slightly 
lower than the outcome of a study conducted in 2012, where 
10% of the samples of Danish retail pork were found positive for 
MRSA CC398 (56). The Danish studies were based on qualitative 
enrichment methods, thus bacterial loads of MRSA CC398 in 
meat are not known. A study in the Netherlands found that the 
number of CFU/g in 75 MRSA positive meat samples were all less 
than 10 CFU/g (57).
Enterococci have consistently been isolated from both 
Danish and imported pork (2). In 2015, E. faecium was isolated 
from 6.2% and E. faecalis from 61.9% of 194 samples of Danish 
pork. Further studies on the prevalence of enterococci in food 
at point of consumption were on-going at the time of writing 
this article, but results were not yet available. The presence of 
enterococci in meat is considered to be independent of resist-
ance genes and thus, humans are exposed to both resistant and 
sensitive enterococci through meat. Resistance to pleuromuti-
lins is not monitored in enterococci in Denmark, but the preva-
lence of resistance to other antibiotics in enterococcal isolates 
in pork is substantially lower than in live animals (Table  1). 
This may suggest different subpopulations, where resistance in 
the latter reflects the processing environment rather than direct 
contamination of meat during slaughter and dressing (2). 
Handling of meat may lead to transmission of MRSA CC398 
and Enterococcus spp., due to bacteria getting in contact with 
the skin and/or skin abrasions of the meat-handler or via cross 
contamination to foods, which will be eaten uncooked. Still, 
the probability appears to be low (58). This was confirmed in 
a study on the prevalence of MRSA CC398 on three Dutch 
slaughterhouses, which found that direct contact with live 
animals largely determines the carriage of MRSA CC398, 
although some carriers were found among slaughterhouse 
workers without contact with live animals (59).
The bacterial loads of Staphylococcus spp. and Enterococcus 
spp. are expected to decrease drastically, when pork is cooked. 
The only pork products consumed without heat treatment are 
cured and fermented products, such as dry-cured sausages. Also, 
here the loads of bacteria are expected to be low because of the 
presence of Lactobacillus spp. and high sodium concentrations.
Kitchen hygiene in Denmark is assessed as high due to abun-
dant public information and effective control programs in public/
commercial kitchens.
Exposure to MRSA CC398 and Enterococci  
through Direct Contact with Pigs
The main exposure pathway for MRSA CC398 is transmission 
through occupational contact to contaminated livestock holdings 
and in lesser extend subsequent transfer to their household mem-
bers (60). Pigs and humans harbor different types of staphylococci 
primarily in their nasal cavity and secondarily on their skin. 
Exchange of nasal and skin flora is considered a frequent occur-
rence between humans and pigs and colonization of nasal mucosa 
with pig staphylococci is described for people having daily contact 
with pigs, such as farmers and veterinarians. The colonization of 
farmers with MRSA CC398 is well described in Denmark (60, 61).
Human carriage of MRSA CC398 in the nasal cavity may 
persist in a high proportion of people with daily contact to pigs. 
For example, Köck et al. found persistence in up to 59% of such 
persons (45). Persons working at livestock farms, where MRSA 
CC398 is present, do not only include farmers and their family 
members but also veterinarians, pig transporters, and slaughter-
house employees working with live animals—and the probability 
of transmission is considered very high (46). Contrary, single 
farm visits are estimated to be associated with a very low exposure 
risk. In 2015, surveillance data showed that 37% of human car-
riers did not report to have pig contact (but they could have had 
another animal contact), and MRSA CC398 does not appear to 
spread easily between humans in Denmark (61).
Resistance data in DANMAP show marked differences 
between resistance observed in enterococci from animals and 
from humans, thus no significant transmission seems to occur 
(2). A probable but infrequent link between pigs/pork and human 
enterococci has been identified (41, 42). The main transmission 
routes remain unknown (43).
Table 3 | number of carriers of Mrsa cc398 in Denmark based on information from national statistics, relevant literature and expert opinion.
group no. of persons carrier proportion (%) no. of carriers assuming  
all herds positive
no. of carriers assuming 
69% positive herdsa
Swine farmer/employee, full time 8,000b 74c 5,920 4,085
Farm employee, weekly work with swine 1,000d 74e 740 511
Swine veterinarians and advisors with daily contact to swine 200 74e 148 148
Craftsmen with weekly contact or less to swine 7,564d 11f 821 566
Swine transport workers 453d 22g 100 100
Abattoir workers 6,600d 4h 264 264
Household members to all persons listed above 26,199b 6i 1,511 1,073
Remaining society 5,600,000 0.10j 5,607 3,980
Sum of carriers 0.27 15,111 10,615
aResult of a screening in 2014.
bData from Danish Statistics, combined with best guesses among the authors validated through contact to experts.
cUnpublished data from ongoing Danish study into 10 swine herds infected with MRSA CC398. Here, 74% of the employees were positive and 10% of the household members.
dEstimates from the Danish swine industry.
eAs a worst case assumption, it was assumed that weekly work with swine would result in the same carrier rate as daily work with swine, and that swine vets would have the same 
carrier rate as persons with daily contact to swine.
fFor craftsmen with weekly contact or less, it was assumed that 74% would be positive when they leave the farm, but that they will be negative the day after—hence 74%/7 = 11%.
gBased on Van Cleef et al. (62).
hBased on a weighted average of the prevalence observed in abattoir employees presented in Ref. (59, 62, 63).
iAuthors’ best guess based among others on unpublished data described in b. An average household has 2.1 members according to data from Danish Statistics—in the present 
case 1.1 persons apart from the person with contact to swine.
jAuthors’ best guess.
MRSA, methicillin-resistant S. aureus.
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In general, the probability of human exposure to MRSA 
CC398 and enterococci by direct contact with pigs in Denmark 
is estimated to be low, because only relatively few people have 
contact with live pigs. The Danish population consists of 5.7 
million persons, and the Danish employed work force consisted 
of 2.7 million persons (2014). According to Table  3, an esti-
mated 11,000–15,000 persons are probably carriers of MRSA 
CC398—corresponding to around 0.4–0.5% of the work force 
and 0.2–0.3% of the total population. The carriage of enterococci 
of animal origin farmworkers with daily contact to pigs has not 
been investigated.
Other or Unknown Exposure Pathways for  
MRSA CC398 and Enterococci
Methicillin-resistant S. aureus CC398 and enterococci may 
spread by emission to the outside surroundings of positive swine 
farms. MRSA CC398 bacteria have been detected in the air and 
on the ground on the downwind side 150 and 300 m from positive 
barns, respectively. However, the probability of by-passers being 
contaminated with MRSA CC398 was assessed as low, while the 
probability of contamination through contact with soil or crops 
was assessed as low or unknown (55).
Conclusion for the Exposure Assessment
Only few Danes have direct contact to pigs. Thus, the risk of 
exposure to pleuromutilin-resistant MRSA CC398 (and other 
staphylococci of swine origin) or pleuromutilin-resistant entero-
cocci through this route is assessed as low with low uncertainty. 
Other direct transmission routes are also considered to be low 
with medium uncertainty. For staphylococci, the probability of 
foodborne transmission is low (low uncertainty), whereas for 
enterococci, the importance of spreading through the foodborne 
route is unknown (high uncertainty).
consequence assessment
Human and Economic Costs of Infection
It is essential to prevent serious infections with S. aureus and 
enterococci and to secure effective treatment options through 
the control of multidrug-resistant bacteria. Although the human 
pathogenicity of MRSA CC398 and resistant Enterococcus spp. 
is low, it is considered important to prevent the spread of these 
bacteria, especially to weakened and hospitalized patients. The 
costs associated with screening, isolation, and treatment of 
patients with clinical infections due to MRSA CC398 was esti-
mated in Denmark in 2015. For patients admitted to intensive 
care, the expense was estimated to increase twofold due to extra 
precautions, prolonged hospital stay, and more complications, 
amounting to approximately €27,000 per patient (64).
Increased Public Health Burden and Disease  
due to Consumption of Pleuromutilin in Pigs
A retrospective Danish study of human MRSA CC398 isolates 
from 1999 to 2011 showed that infections were primarily associ-
ated with skin and soft tissues and other noninvasive infections 
(60). The same study reported the incidence of MRSA CC398 
infections in 2011 to be 1.1 per 100.000 person-years. In Denmark, 
human MRSA is notifiable, and clinical MRSA isolates are referred 
mandatorily to the reference laboratory at Statens Serum Institut. 
In 2012, the Danish Health and Medicines Authority published a 
revised MRSA guideline, which introduced contact with pigs as 
a new risk factor for carriage of the bacteria. Therefore, persons 
working with pigs and household members of such persons 
are tested for MRSA routinely on admission to hospital. This 
has given a greater share of findings of healthy carriers and has 
contributed to effective control of spread at Danish hospitals (60). 
In 2015, a total of 1,173 MRSA CC398 carriers were detected 
through the screening program (39% of all described human 
Table 4 | human cases of bacteremia and death in Denmark, distributed according to type of staphylococci, for the time period 2011 to mid-2016.
Kind of staphylococci Year 30-day mortality (%)
2011 2012 2013 2014 2015 2016a
MSSA bacteremia 1,504 1,507 1,735 1,908 1,973 b
MSSA deaths 347 337 408 425 452 b 23
Non-CC398 MRSA bacteremia 20 19 26 48 26 13
Non-CC398 MRSA deaths 6 4 6 10 6 3 23
CC398 MRSA bacteremia 1 2 4 8 3 5
CC398 MRSA deaths 0 1 2 2 1 0 26
Source: annual report from Statens Serum Institut (www.ssi.dk).
aOnly data from the first 6 months of 2016 were available.
bFigures for MSSA 2016 were not available by February 2017.
MSSA, methicillin-sensitive S. aureus; MRSA, methicillin-resistant S. aureus.
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MRSA carriers) (48). In all, 208 were clinical infections, and of 
these 3 were bacteremia cases—corresponding to 3/1.173 = 0.3% 
of the identified carriers. Throughout the period from 2007 to 
2016, the share of cases with clinical infection in Denmark was 
lower for MRSA CC398 than that observed for the remaining 
types of MRSA (Table 4).
Resistance testing of all human MRSA is performed at the 
Clinical Microbiological Departments for treatment purposes 
only, and data from these are thus not officially reported. At 
Statens Serum Institut, a share of the referred clinical strains 
is tested with the TREK microtiter system. None were found 
resistant to linezolid (Table 1) (2). Thus, none of the examined 
human cases with MRSA CC398 could be attributed directly to 
pleuromutilin resistance. In theory, selected mutants of S. aureus 
resistant to linezolid can exhibit cross-resistance to tiamulin (17). 
However, data on linezolid resistance are a poor indicator of the 
presence or absence of pleuromutilin resistance due to only partly 
overlaps of resistance mechanisms.
Enterococcus faecalis is the frequent cause of urinary tract 
infections. These are usually mild but may be recurrent espe-
cially in the elderly and in patients with urinary catheters. In 
some of these patients, bacteremias and endocarditis develop. 
Resistance testing on enterococcal urinary strains does not 
include testing for linezolid, thus the burden due to consump-
tion of pleuromutilins could not be estimated but it was judged 
to be negligible.
Prolonged Human Illness and/or Death  
due to Consumption of Pleuromutilin in Pigs
Treatment failure was defined as prolonged human illness and/or 
death due to resistance to pleuromutilins.
In 2015, the incidence of bacteremia with presence of 
S. aureus in Denmark was estimated to be 36.7 cases per 100,000 
inhabitants, corresponding to 1,973 bacteremia cases (2). MRSA 
accounted for 29 of these, and 3 of these were MRSA CC398 
(Table  4). Until mid-2016 altogether six deaths with MRSA 
CC398 have been reported (based among others on reference 48 
including corrections presented in Table 4). All of these suffered 
from severe comorbidity or prolonged illness. In general, the 
30-day mortality due to staphylococcal bacteremia is high, for 
2011 to 2016, the 30-day mortality was 23% for MSSA and 26% 
for MRSA (Table 4) (2).
A Danish study published in 2013 estimated the disease bur-
den due to severe enterococcal infections (65). The incidence was 
found to be increasing during recent years and was estimated to 
19.6/100,000 person-years. Most enterococcal bacteremias were 
found to be associated with hospitalization. Although E. faecalis 
was mainly associated with urinary tract infections as the primary 
cause of bacteremia, E. faecium was primarily associated with 
abdominal surgery. The 30-day mortality was high for patients 
with bacteremias—21.4% in patients with E. faecalis and 34.6% 
in patients with E. faecium.
Only a fraction of enterococcal isolates from blood cultures 
will usually be tested for sensitivity to linezolid. At Rigshospitalet 
(a highly specialized tertiary hospital in the Capital Region), all 
clinical enterococcal strains (N=1,715) isolated from November 1, 
2015, to November 1, 2016, were tested for phenotypical resist-
ance to linezolid. Of the 41 linezolid resistant strains, six were 
sent to the reference laboratory at Statens Serum Institut for 
whole-genome sequencing. In one linezolid-resistant E. faecalis, 
an optrA gene was found. This belonged to the sequence type 
(ST) 16, a ST that has previously been associated with pigs 
(Personal communication, A. Hammerum, Statens Serum 
Institut, 2017).
Although surveillance on the spread of clinical VRE exist, based 
on voluntary referral from the Danish Clinical Microbiological 
Departments to the reference laboratory at Statens Serum Institut, 
this does not include registration of prolonged illness or deaths 
due to these.
None of the approximately 300 clinical VRE submitted to 
Statens Serum Institut for whole-genome sequencing carried the 
optrA gene (Personal communication, A. Hammerum, Statens 
Serum Institut, 2017). The strains were not examined for the 
presence of other transmissible genes but the resistance profiles 
of the tested strains suggested that none cfr-carrying strains were 
among them.
It is difficult to establish whether the high mortality of staphy-
lococcal and enterococcal bacteremias would be influenced 
by an additional resistance to pleuromutilins or linezolid. For 
vulnerable groups—such as hospitalized and immunocompro-
mised—the probability of negative consequences will be high, if 
the general resistance pressure increases. The risk for acquiring 
an infection with a multiresistant strain increases with increased 
length of stay and in patients who are admitted to intensive care 
FigUre 2 | summary of risk assessment for human health related to use of pleuromutilins in Danish pigs.
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or have undergone abdominal surgery. This often leads to long-
lasting catheterization and the risk of colonization of indwelling 
catheters with multiresistant bacteria. These patients will often 
be treated with several antimicrobial courses, and this eventually 
causes a shift in the microbiological flora from more sensitive 
toward more resistant strains. Prolonged antibiotic treatment will 
also select for already resistant bacteria among the microbiome 
of the patient.
For patients suffering from infections with E. faecalis or 
E. faecium, treatment failure mainly occurs in severely ill 
patients with bacteremia, significant comorbidities, and long 
hospitalization. For staphylococcal infections, treatment fail-
ure is mainly seen in complicated cases of bacteremia with no 
established primary focus for the infection or in bone infec-
tions, where the infecting strain might adjust to the human 
host and show slow or no response to the antimicrobial 
treatment.
For these very vulnerable patient groups with multidrug resist-
ant bacteria, linezolid and the anticipated new pleuromutilin for 
systemic treatment may constitute a relevant antimicrobial to 
consider. In addition, the consequences due to already existing 
pleuromutilin- or linezolid-resistant strains will be severe for the 
individual patient.
Today, the prevalence of multidrug-resistant gram-positive 
human infections in Denmark in general is very low (2) and very 
few patients are treated with linezolid. No treatment failure due 
to linezolid has been reported in Denmark so far.
Partial Conclusion for the Consequence Assessment
Human carriage of MRSA CC398 and urinary tract infections with 
enterococcal strains are fairly common, whereas severe infections 
with MRSA CC398 happen only rarely and severe infections with 
enterococci are mainly associated with prolonged hospitalization. 
Pleuromutilin is not used for humans in Denmark, and linezolid 
is only used rarely, in specific hospital settings and in selected 
patient groups. However, linezolid is a last line drug reserved for 
the few infections, where other antimicrobials cannot be used. 
Therefore, the consequence assessment for MRSA CC398 was 
assessed as very low probability for the public in general, but high 
for vulnerable groups (low uncertainty), whereas for pleuromu-
tilin resistant Enterococcus, it was assessed that there was a low 
probability of adverse consequences across the population (high 
uncertainty).
DiscUssiOn
risk estimate
The current risk for human health-associated consumption of 
pleuromutilins in Danish swine was assessed as low under the 
current conditions. This is an increase compared to the previous 
assessment conducted in 2010, where a very low risk was found 
(7). A summary of the different elements of the risk assessment is 
presented in Figure 2.
The consumption of pleuromutilins in Denmark is low 
compared to other European countries (9) and has not changed 
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markedly over the past 20 years. It may be considered a controversy 
to call a use involving 8,000 kg of antimicrobials in livestock low, 
yet it should be taken into account that the annual production of 
pigs in Denmark is 28 million (compared to a human population 
size of close to 6 million). The relative low use is due to awareness 
of and focus on the antimicrobial resistance issues in Denmark 
and strict prescription and usage policies prohibiting both use 
as growth promoter and preventive use of antibiotics in animals.
Among these policies, the Yellow Card Scheme has shown 
to have substantial influence on the overall consumption of 
antimicrobials in pigs. The newest version of the scheme differ-
entiates between weighing of different antibiotic groups: a farmer 
using, e.g., fluoroquinolones will reach the allowed limit for the 
herd very quickly, since the consumption of fluoroquinolones 
is multiplied by 10 when the average consumption per pig is 
calculated. The weights for tetracyclines are currently 1.2 (and 
by 1.5 from September 30, 2017) and 0.95 for simple penicillin, 
sulfonamides, trimethoprim, and pleuromutilins (5). The allowed 
limits are repeatedly adjusted, and from March 2017 the limit for 
consumption for sows with piglets were reduced to 4.1 weighted 
ADD (ADDw) per 100 animals per day, for weaners to 21.8 ADDw 
per 100 animals per day, and for finishing pigs to 5.6 ADDw  
per 100 animals per day (4).
In general, the need for antimicrobial treatment of Danish pigs 
may be lower than in many other countries, because dysentery 
has been eradicated from the majority of swine herds. Pig health 
is high in the Danish pig production due to a widely used SPF 
Certification scheme. The SPF sow herds produce piglets, boars, 
and gilts for almost all production herds, and the majority of the 
sow herds are SPF certified with public access to data describing 
the sow herds’ infection status. Hereby, finishing pig producers 
can purchase replacement animals with the same infection status 
as in their own herd, minimizing the risk of introduction of 
additional unwanted pathogens.
The hazard identification showed that pleuromutilin resistance 
may be transmitted from pigs to humans in various ways and by 
different kinds of bacteria, but it also showed that the knowledge 
about the importance of these ways was limited making it difficult 
to distinguish potential hazards from risks.
The release assessment showed that pleuromutilin resistance 
is present in MRSA CC398 in non-negligible levels in Denmark, 
suggesting a potential risk pathway to humans. This may have a 
negative impact on especially immunocompromised persons, if 
cross-resistance to linezolid becomes more prevalent.
The exposure assessment showed that despite that MRSA 
CC398 is present in the majority of the Danish swine herds, only 
a small proportion of the human population are carriers of MRSA 
CC398. This number might be increasing since one-third of the 
found carriers were not associated with regular contact to swine 
and thus might constitute a pool of exposure to vulnerable per-
sons not covered by the existing screening guidelines, and hence 
the probability of negative consequences may increase. The pres-
ence of enterococci in meat was high, but appropriate handling 
and cooking reduce the foodborne exposure to low. Very little is 
known about the human exposure of Enterococcus spp. through 
direct contact with pigs, but since a low proportion of Danes are 
exposed to living pigs, it was also assessed as low.
It is difficult to estimate the additional burden on severe dis-
ease and death due to pleuromutilin- or linezolid-resistant MRSA 
CC398 and enterococci, since death by these bacteria often occurs 
in already severely ill patients and at a late stage in hospitaliza-
tion. It is difficult to judge whether possible additional resistance 
mechanisms in these patients contribute to the increased mortal-
ity observed, selected due to prolonged antimicrobial treatment.
Several attempts have been made to estimate the number of 
significant human disease and deaths due to resistant bacteria. In 
2009, the European Center for Disease Control (ECDC) published 
a report on the disease burden due to resistant bacteria based on 
European surveillance data from 2007 (66). The report estimated 
the number of additional deaths due to resistant bacteria to be 
25,000 annually. The estimate was based on a calculated total 
number of 171,200 bacteremias with MRSA causing an estimated 
5,400 deaths and 18,100 bacteremias with vancomycin-resistant 
E. faecium causing 1,500 deaths. The McCabe score for modeling 
the expected extra deaths occurring from these infections (67) 
could not be used since information on pleuromutilin resistance 
is lacking in the clinical strains from bacteremia and since the 
relevant bacteria are already multiresistant. We assumed that the 
presence of the pleuromutilin-resistance mechanism itself does 
not contribute to more severe disease or death. Especially since 
pleuromutilins are not used in human treatment.
Still, it must be assumed that the use of pleuromutilins will 
increase the release of MRSA CC398 and resistant enterococci 
from pigs to a certain degree, as will the consumption of other 
antimicrobials conferring coresistance to pleuromutilins.
In Denmark, multiresistance in human pathogens is not 
endemic, and screening procedures and infection control 
measures at hospitals are very effective. This, combined with the 
fact that MRSA CC398 does not seem to have a high speed of 
transmission from pigs to humans or between humans, makes 
it plausible to estimate the risk of impact on human health to 
be altogether low. This also applies to multiresistant enterococci, 
where no significant transmission from pigs to humans yet has 
been described. However, a theoretical possibility of transmission 
of resistance genes does exist.
Uncertainty and its implications  
for Predictions into the Future
The assessment was associated with some uncertainty due to lack of 
data and is very dependent on the current very low occurrence of 
mobile, genetic resistance mechanisms, low incidence of multidrug-
resistant bacteria in the Danish population in general, and a very 
rare need for “last choice drugs” in severely ill patients. While the 
Danish surveillance system for many years has covered bacteria with 
known human pathogenicity, surveillance on other than known 
human pathogen bacteria such as commensals, and the occurring 
phenotypic resistance and resistance mechanisms in these is missing.
The analysis showed that resistance transfer between species 
is complex and multifactorial. It is unlikely that all transmission 
pathways are known to us today. Sporadic findings are often 
reported, but lack of repeatability and data restricts the ability to 
assess how important such findings are and whether they pose a 
risk to public health. This also includes the lack of surveillance of 
resistance in anaerobe bacteria. The gram-positive anaerobe gut 
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flora in pigs and humans might constitute a pool for resistance 
mechanisms, which constantly exchanges with other bacteria, 
including the ones that more frequently cause human disease.
The increased use of whole-genome sequencing is likely to 
provide additional valuable knowledge on transfer and potential 
resistance risks, but the link to phenotypic and clinical resistance 
and, thus, importance for public health remain to be elucidated.
Mathematical modeling is a valuable tool in simulating path-
ways and identifying ways of reducing resistance. However, the 
relationship between reducing consumption of antibiotics and 
reducing resistance is not necessarily linear and still needs to be 
established for modeling to have full value. This includes among 
others the fact that some resistance mechanisms are unlikely to 
reverse if they are associated with increased fitness for the bacteria 
(68, 69). Furthermore, data and knowledge gaps cause problems 
in modeling too and enhance uncertainty around outputs.
When new relevant data become available indicating that 
there might be a change in resistance prevalence or consumption 
patterns, the present risk assessment should be repeated. This 
is especially important if the consumption of pleuromutilins 
increases substantially, and this leads to a higher prevalence of 
mobile, easily transferrable resistance mechanisms of importance 
to human health, or if linezolid and pleuromutilins becomes more 
important in human medicine.
The choice of risk assessment 
Framework
The risk related to antimicrobial resistance may be assessed in 
different ways. One simple way may be to use the WHO ranking 
of critically important antimicrobials, which in essence is based 
on the worldwide need for treatment in human medicine (70). 
The drawback of this approach is that it does not take into account 
differences between countries in antimicrobial consumption and 
resistance, meaning that critically important antimicrobials will 
not necessarily be critically important everywhere. In addition, it 
does not take into account whether surveillance or any data from 
research show that a specific veterinary use is associated with a 
non-negligible risk for humans in a given country or region.
We were inspired by the EMA framework, which includes 
the risk pathway in details; from the use of pleuromutilin in pigs 
to the consequences in humans. Initially, we followed the EMA 
framework very stringent, in the exact order and in details for the 
many elements listed. This systematic approach was very effective 
to point out important gaps in the surveillance and knowledge of 
transmission routes and rates (8). However, the framework was 
too comprehensive for our purpose, led to a plethora of details 
on the expense of the overview, and thus was abandoned. While 
the EMA framework was developed for introduction of a new 
drug on the market with unknown mechanisms and risks, our 
study was assessing an established antibiotic with existing—albeit 
not perfect—surveillance data. The complexity of the EMA 
framework added unnecessary areas of uncertainty and compli-
cated communication of the results to relevant audience of our 
assessment.
In addition, the EMA framework does not specify how the 
hazard identification should be undertaken and which criteria 
should be used to distinguish hazards from potential risks, for 
which a risk assessment is required. Should the selection, e.g., be 
based solely on resistance mechanisms where treatment failure 
is observed or is presence of resistance in bacteria from animals 
in itself a sufficient argument? Moreover, should the hazard 
identification be based on national or international findings? We 
decided to use international data for the hazard identification and 
national data for the release, exposure, and consequence assess-
ment. We also decided to focus on the different ways in which 
resistance can be dispersed, and here the bacteria may be seen 
as a vehicle, not the hazard in itself. Moreover, we found that the 
EMA framework was most appropriate for resistance forms that 
are bound to specific bacteria with well-described transmission 
routes from animal to humans. In the case of transmission of 
mobile resistance genes, which may travel between different 
bacterial species at high speed, the EMA framework suffers 
from being insufficient, especially because the bacteria species is 
considered the hazard, not the drug use or the resistance genes.
The effect on the environment was not assessed as this is outside 
the scope of the framework developed by EMA. In line, off-label 
use—including misuse—was not included in the analysis, but it is 
considered a very minor issue in Denmark. These shortcomings 
and limitations could be addressed in future research.
As far as we are aware, this is the first public-accessible 
publication based on the framework developed by EMA for the 
assessment of the public health risk related to use of antimicrobi-
als in livestock. The output is a risk assessment, which is one part 
of the risk analysis process. Other elements are risk management 
and risk communication. EMA states that this guidance aims to 
provide a systematic approach to the evaluation of the associated 
scientific data and to improve the transparency and consistency 
of the regulatory decision-making process—we agree that the 
guideline can be used for this purpose but that flexibility should 
be applied to ensure logic and easy communication to the relevant 
audience.
recommendation
Care should be taken to ensure a prudent use of antibiotics in 
livestock and only for treatment of disease, metaphylaxis, and 
planned eradication. Moreover, long-term treatments should be 
avoided. This will ensure that pleuromutilins will remain effec-
tive for the treatment of swine also in the future. In line, swine 
dysentery should be eradicated, because this will reduce the need 
for treatment (9).
For most indications for which pleuromutilins are authorized, 
tetracyclines and macrolides can replace pleuromutilins, except 
for dysentery. But these antimicrobial classes are not perceived 
as having a lower risk for human health than pleuromutilins. 
Therefore, pleuromutilins were still recommended by the work-
ing group for sensible use in Danish swine for treatment of the 
relevant infection.
The newest changes to the Yellow Card scheme are likely to 
lead to a slightly higher use of pleuromutilins but to a lower use 
of other antimicrobial classes that coselect for pleuromutilin 
resistance (4). It is difficult to predict the consequences of this 
management decision, which was implemented just before this 
analysis was done. In January to November 2016, the increase 
in consumption of pleuromutilin was limited to 0.3% compared 
14
Alban et al. Pleuromutilins: Risk Assessment and Guidelines
Frontiers in Veterinary Science | www.frontiersin.org May 2017 | Volume 4 | Article 74
to the same months in 2015. However, the consumption may 
increase in the future, and it emphasizes the need to monitor on 
the consumption of pleuromutilins and their resistance mecha-
nisms in Danish pigs and to reassess the risk, if any risk factors to 
human health changes.
In line with EMA, we recommend the establishment of routine 
monitoring of pleuromutilin resistance in relevant swine bacteria 
to develop an early warning system (9). Pleuromutilin resistance 
is not monitored systematically in Denmark, and therefore, it is 
extremely difficult to estimate the contribution to the prevalence 
of MRSA CC398 and enterococci within pig farms and the preva-
lence of resistance mechanisms.
As resistance in both human and swine pathogens seems to 
be emerging, there is a need for targeted surveillance of specific 
resistances. Focus on Staphylococci spp.—including a genetic 
component to search for resistance genes—is recommended. At 
present, there is no systematic monitoring of Staphylococcus spp. 
or MRSA in pigs in Denmark. Enterococcus spp. are monitored as 
part of the program for monitoring of resistance to erythromycin, 
linezolid, and chloramphenicol—but this does not involve moni-
toring for resistance to pleuromutilins. The emergence of VRE in 
hospital settings is of special concern. A program for surveillance 
is being established in collaboration between clinical micro-
biological departments and the Danish health authorities. This 
surveillance program is expected to cover the emerging resistance 
for linezolid as well. In the existing collaboration between the 
veterinary authorities, DTU FOOD, and Statens Serum Institut, 
the establishment of a more thorough surveillance of resistance 
mechanisms is being discussed.
cOnclUsiOn
The current risk for human health associated with consumption 
of pleuromutilins in Danish swine was assessed as low under the 
current conditions. This is an increase compared to the previous 
assessment where a very low risk was found.
Two hazards were identified: MRSA CC398 and enterococci. 
For MRSA CC398, the total risk was estimated as low (low uncer-
tainty). For enterococci, the total risk was estimated as low (high 
uncertainty).
The assessment should be repeated, if pleuromutilin consump-
tion increases substantially, resulting in increased prevalence of 
mobile, easily transmissible resistance mechanisms, or if the need 
for linezolid as a last line human drug increases. Continuous 
monitoring of pleuromutilin resistance in selected human patho-
gens should therefore be considered.
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